Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751644 | 0.72 | NFKB1 (0.31) | TP53MAPTALOX15HSD17B10 | |
| SCHEMBL25195357 | 0.67 | CA12 (0.34) | TP53MAPTALOX15HSD17B10 | |
| Hydrochloric Acid SCHEMBL27029865 | 0.66 | CA12 (0.33) | TP53MAPTALOX15HSD17B10 | |
| SCHEMBL29386151 | 0.66 | TP53 (0.33) | TP53MAPTALOX15HSD17B10 | |
| SCHEMBL27771574 | 0.66 | TP53 (0.31) | TP53MAPTALOX15HSD17B10 | |
| SCHEMBL3354761 | 0.66 | TP53 (0.33) | TP53MAPTALOX15HSD17B10 | |
| SCHEMBL8545778 | 0.65 | TP53 (0.35) | TP53MAPTALOX15HSD17B10 | |
| SCHEMBL29080196 | 0.64 | TP53 (0.34) | TP53MAPTALOX15HSD17B10 | |
| SCHEMBL22289959 | 0.64 | GABRA1 (0.39) | ALOX15 | |
| SCHEMBL13947269 | 0.62 | TP53 (0.36) | TP53MAPTALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | HTR2C, HTR4, HTR1A | TP53 4830/4885MAPT 4526/4885ALOX15 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.